Preparation method of polymer / GO / Ga stent with anti-infection and osteogenic differentiation dual functions
By using selective laser sintering technology in the treatment of osteomyelitis, the polymer/GO/Ga stents prepared by using selective laser sintering technology, the difficulty of liquid gallium aggregation during the molding process and the side effects and drug resistance of existing treatment methods are solved, and drug-free resistance is achieved and efficient antibacterial treatment and bone regeneration effects.
Patent Information
- Application Number
- CN202411173550.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
The existing treatment methods for osteomyelitis have great side effects, strong drug resistance and difficulty in completely removing bacteria. It is difficult to accumulate liquid gallium during molding, which affects its application in the treatment of osteomyelitis.
Selective laser sintering technology is used to prepare polymer/GO/Ga scaffolds, and Ga nanoparticles are electrostatically adsorbed on GO nanosheets and mixed with polymers to form a scaffold with anti-infection and osteogenesis.
It achieves drug-resistant and efficient antibacterial treatment, reduces disease recurrence, and the pore structure of the stent promotes bone regeneration and improves osteogenesis efficiency.
Smart Images

Figure CN119055842A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedical materials, and more specifically, relates to a method for preparing a polymer / GO / Ga scaffold with dual functions of anti-infection and osteogenic differentiation. Background Art
[0002] Osteomyelitis is a complex disease that develops from a bacterial infection that affects the deeper tissues, leading to degeneration and death of bone tissue. Acute osteomyelitis can progress to chronic osteomyelitis, which is difficult to treat and can last for a long time without treatment. Osteomyelitis is one of the most devastating orthopedic diseases and in severe cases may require amputation.
[0003] The main treatments currently available include surgical debridement and systemic and local antibiotic therapy. Although surgical debridement can effectively reduce inflammation in the bone marrow cavity, it may not completely eliminate all dangerous pathogens and may reduce limb function and the patient's quality of life. Early systemic antibiotics can effectively treat osteomyelitis, and chronic systemic and local antibiotics can also inhibit pathogenic bacteria in the bone marrow cavity to a certain extent. However, long-term use of high-dose antibiotics can lead to systemic side effects and the emergence of drug-resistant strains. Therefore, finding a new method for the treatment of osteomyelitis that is highly effective, has few side effects, and is non-resistant is an urgent clinical problem that needs to be solved.
[0004] Liquid metal gallium (Ga) is a new type of biomedical material that has attracted much attention due to its good biocompatibility and easy modification. In recent years, due to its antibacterial, bone resorption inhibitory, and bone growth promoting effects, its application in bone tissue engineering has developed rapidly. In addition, Ga nanoparticles (Ga NPs) can continuously release Ga ions (Ga 3+ ). As we all know, Ag + 、Zn 2+ , Cu 2+ 、Ce 3+ , Ga 3+ Metal ions such as Ga have broad-spectrum antibacterial activity and no bacterial resistance. 3+ It is particularly outstanding for its special antibacterial function and low toxicity. In addition, Ga has been approved by the US Food and Drug Administration (FDA) for high-dose intravenous injection to treat hypercalcemia in malignant tumors.
[0005] Ga 3+ The specific antibacterial function of bacteria is mainly due to the 3+ The demand for Ga is greater than that of normal cells. 3+ and Fe 3+ The high chemical similarities, such as ionic radius, ionization potential, and electron affinity, make it challenging to distinguish them in biological systems. 3+In comparison, Ga 3+ It is not redox active under physiological conditions, which prevents the activation of various iron-dependent redox pathways. 3+ As a "Trojan horse", it destroys bacterial iron metabolism and achieves bactericidal function. However, the liquid properties of Ga at room temperature pose great challenges in molding and are prone to aggregation, which seriously affects its potential application in the treatment of osteomyelitis. Summary of the invention
[0006] An object of the present invention is to solve at least the above problems and / or disadvantages and to provide at least the advantages which will be described hereinafter.
[0007] In order to achieve these purposes and other advantages according to the present invention, a method for preparing a polymer / GO / Ga scaffold with dual functions of anti-infection and osteogenic differentiation is provided. First, Ga nanoparticles are electrostatically adsorbed on the surface of GO nanosheets to prepare GO / Ga powder, and then the GO / Ga powder and high molecular polymer powder are uniformly mixed by grinding according to a proportion, and then the polymer / GO / Ga scaffold is prepared by selective laser sintering technology.
[0008] Preferably, the high molecular polymer powder is at least one of left-handed polylactic acid PLLA powder, right-handed polylactic acid PDLA powder, racemic polylactic acid PDLLA powder, optically inactive polylactic acid Meso-PLA powder, polycaprolactone PCL powder, polyglycolic acid PGA powder, polylactic acid-glycolic acid copolymer PLGA powder and polydioxanone PPDO powder.
[0009] Preferably, in the polymer / GO / Ga scaffold, the mass fraction of GO / Ga powder is 1-10wt%, the mass fraction of high molecular polymer powder is 90-99wt%, the particle size of GO / Ga powder is 0.1-2μm, and the particle size of high molecular polymer powder is 0.1-100μm.
[0010] Preferably, the method comprises the following steps:
[0011] Step 1: Gallium nanomaterials are prepared using nanoprobe ultrasonic technology. The specific method includes: heating metal gallium at 60°C for 10 minutes to obtain liquid metal gallium, and taking out 40 mg of liquid gallium from the liquid gallium and adding it to a glass bottle containing 20 μL 1M HCL and 5 mL ethylene glycol. Ethylene glycol is used as a dispersion stabilizer for nanoparticles. Then, the solution is ultrasonicated for 2 hours (on for 15 seconds, off for 2 seconds) using a nanoprobe ultrasonic technology with a power of 150 W to obtain a GaNPs colloidal ethylene glycol solution (concentration of 8 mg / mL), which is centrifuged, washed with anhydrous ethanol, and dried under a vacuum environment to obtain Ga nanoparticles.
[0012] Step 2: adsorbing GaNPs onto GO nanosheets by electrostatic adsorption to synthesize GO / Ga powder. The specific method includes: adding 20 mg of graphene oxide powder to the GaNPs colloidal ethylene glycol solution prepared above, and continuing to sonicate for 30 minutes (on for 15 seconds, off for 2 seconds) under a nanoprobe ultrasonic technology with a power of 150 W to obtain a GO / Ga colloidal ethylene glycol solution, and finally centrifuging, adding anhydrous ethanol for washing, and drying under a vacuum environment to obtain GO / Ga powder;
[0013] Step 3: Weigh GO / Ga powder and high molecular polymer powder in a specific mass ratio as required, place them in a grinding mortar and grind them for 10 to 30 minutes to fully mix the powders. Then, place the evenly mixed powders in a selective laser sintering system, select an appropriate three-dimensional model, spread the powders evenly on a substrate, and sinter layer by layer to finally obtain a polymer / GO / Ga scaffold with both anti-infection and osteogenic dual functions.
[0014] Preferably, in step 1, the mass volume ratio of gallium, HCL and ethylene glycol solution is 40 mg:20 μL:5 mL; the drying temperature under vacuum environment is 20° C., and the vacuum drying time is 12 hours.
[0015] Preferably, in step 2, the mass volume ratio of gallium, graphene oxide, HCL and ethylene glycol solution is 40 mg:20 mg:20 μL:5 mL; the vacuum drying temperature is 40° C., and the vacuum drying time is 12 hours.
[0016] Preferably, in the step three, during the selective laser sintering process, the process parameters of the selective laser sintering are: laser power of 1 to 3 W, scanning speed of 100 to 300 mm / s, scanning spacing of 0.05 to 0.1 mm, spot diameter of 0.3 to 1.0 mm, and powder coating thickness of 0.05 to 0.15 mm.
[0017] Preferably, the prepared polymer / GO / Ga scaffold has a porosity of 50-60% and a pore size of 200-500 μm.
[0018] Preferably, the prepared polymer / GO / Ga scaffold is applied in the field of biomedical materials.
[0019] The beneficial effects of the present invention are as follows:
[0020] (1) Compared with the traditional method of treating osteomyelitis, the invention has the following advantages: Gallium ions (Ga 3+ ) achieves its antibacterial effect by interfering with the iron metabolism mechanism inside bacteria, and will not produce bacterial resistance. Therefore, it has the advantages of good efficacy, few side effects, effective reduction of disease recurrence, and simple operation. The selected gallium as an antibacterial agent has good biocompatibility, and Ga3+ It can inhibit osteoclast differentiation, GO can promote osteoblast differentiation, has the ability to promote cell proliferation and osteogenic differentiation, and is beneficial to bone regeneration after antibacterial treatment. The selected high molecular polymer as a biodegradable material has the advantages of excellent biodegradability, biocompatibility, processability and high mechanical strength. The scaffold prepared by selective laser sintering technology can be customized according to differentiated needs to meet the actual use needs to the greatest extent, and the scaffold model is designed to have a suitable porosity and pore size, which is beneficial to the degradation of the scaffold after implantation, cell adhesion and the exchange of nutrients and metabolites, thereby improving the osteogenesis efficiency.
[0021] (2) One purpose of the present invention is to kill bacteria and cure osteomyelitis by using gallium ions (Ga 3+ ) interferes with the iron metabolism mechanism inside bacteria to achieve its antibacterial effect. GO is selected as the carrier of GaNPs. GO nanosheets contain many oxygen-containing groups. These functional groups can provide ideal sites for GaNPs attachment through electrostatic effects, which helps to improve the stability and dispersibility of GaNPs. GO nanosheets also have certain antibacterial ability, and their antibacterial effect is mainly attributed to the membrane damage related to oxidative stress. At the same time, they can also destroy the bacterial membrane through physical damage and can be used for local treatment of implant-related osteomyelitis. Therefore, combining GO nanosheets with GaNPs can have a significant synergistic antibacterial effect.
[0022] (3) Another purpose of the present invention is to promote bone regeneration after osteomyelitis treatment to achieve the ultimate goal of patient recovery. Ga has good biocompatibility, and the Ga released by Ga 3+ Ions have the ability to inhibit osteoclast differentiation. In addition, GO can promote osteoblast differentiation. At the same time, the prepared scaffold has appropriate porosity and pore size, which is conducive to the degradation of the scaffold, cell adhesion, and the exchange of nutrients and metabolites, thereby improving the osteogenic ability of the scaffold.
[0023] Other advantages, objectives and features of the present invention will be embodied in part through the following description, and in part will be understood by those skilled in the art through study and practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] The present invention is further described below in conjunction with the accompanying drawings and embodiments.
[0025] Figure 1 This is a transmission electron microscope image of the GO / Ga powder prepared in the present invention;
[0026] Figure 2 This is a schematic diagram of a model of a poly (L-lactic acid) / GO / Ga scaffold (PLLA / GO / Ga) having both anti-infection and osteogenic functions prepared by the present invention;
[0027] Figure 3 The relative antibacterial rate of the poly (L-lactic acid) / GO / Ga scaffold (PLLA / GO / Ga) and PLLA, PLLA / GO, PLLA / Ga scaffolds prepared by the present invention co-cultured with Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) for 1 day;
[0028] Figure 4 The results of cell counting (CCK-8) of co-culturing rat bone marrow mesenchymal stem cells (rBMSCs) with the poly (L-lactic acid) / GO / Ga scaffold (PLLA / GO / Ga) and PLLA, PLLA / GO, and PLLA / Ga scaffolds prepared by the present invention for 1 day, 3 days, and 5 days;
[0029] Figure 5 This is the alkaline phosphatase (ALP) staining result of PLLA scaffold and rBMSCs co-cultured for 7 days;
[0030] Figure 6 This is the alkaline phosphatase (ALP) staining result of PLLA / GO scaffold co-cultured with rBMSCs for 7 days;
[0031] Figure 7 This is the alkaline phosphatase (ALP) staining result of PLLA / Ga scaffold co-cultured with rBMSCs for 7 days;
[0032] Figure 8 This is the alkaline phosphatase (ALP) staining result of PLLA / GO / Ga scaffold and rBMSCs co-cultured for 7 days. DETAILED DESCRIPTION
[0033] The present invention is further described in detail below in conjunction with the accompanying drawings so that those skilled in the art can implement the invention with reference to the description.
[0034] It should be understood that the terms such as “having”, “including” and “comprising” used herein do not exclude the existence or addition of one or more other elements or combinations thereof.
[0035] Example: See Figure 1-8 The method for preparing a polymer / GO / Ga scaffold with dual functions of anti-infection and osteogenic differentiation is shown, which is characterized in that GaNPs are first adsorbed on the surface of GO nanosheets by electrostatic adsorption to prepare GO / Ga powder, and then the GO / Ga powder and high molecular polymer powder are evenly mixed by grinding according to a proportion, and then the polymer / GO / Ga scaffold is prepared by selective laser sintering technology.
[0036] In this embodiment, the high molecular polymer powder is at least one of left-handed polylactic acid PLLA powder, right-handed polylactic acid PDLA powder, racemic polylactic acid PDLLA powder, optically inactive polylactic acid Meso-PLA powder, polycaprolactone PCL powder, polyglycolic acid PGA powder, polylactic acid-glycolic acid copolymer PLGA powder and polydioxanone PPDO powder.
[0037] In this embodiment, in the polymer / GO / Ga scaffold, the mass fraction of GO / Ga powder is 1-10wt%, the mass fraction of high molecular polymer powder is 90-99wt%, the particle size of GO / Ga powder is 0.1-2μm, and the particle size of high molecular polymer powder is 0.1-100μm.
[0038] In this embodiment, the following steps are included:
[0039] Step 1. Gallium nanomaterials are prepared using nanoprobe ultrasonic technology. The specific method includes: heating metallic gallium at 60°C for 10 minutes to obtain liquid metallic gallium, and taking out 40 mg of liquid gallium from the liquid gallium and adding it to a glass bottle containing 5 mL of ethylene glycol containing 20 μL of 1M HCl. Ethylene glycol is used as a dispersion stabilizer for nanoparticles. The solution is ultrasonicated for 2 hours (on for 15 seconds, off for 2 seconds) using a nanoprobe ultrasonic technology with a power of 150 W to obtain a GaNPs colloidal ethylene glycol solution (concentration of 8 mg / mL), which is centrifuged, washed with anhydrous ethanol, and dried under vacuum to obtain Ga nanoparticles.
[0040] Step 2: Adsorb GaNPs onto GO nanosheets by electrostatic adsorption to synthesize GO / Ga powder. The specific method includes: adding 20 mg of graphene oxide powder to the GaNPs colloidal ethylene glycol solution prepared above, and continuing to ultrasonicate for 30 minutes (on for 15 seconds, off for 2 seconds) under nanoprobe ultrasonic technology with a power of 150 W to obtain GO / Ga colloidal ethylene glycol solution, and finally centrifuging, adding anhydrous ethanol for washing, and drying under a vacuum environment to obtain GO / Ga powder.
[0041] Step 3: Weigh GO / Ga powder and high molecular polymer powder in a specific mass ratio as required, place them in a grinding mortar and grind them for 10 to 30 minutes to fully mix the powders. Then, place the evenly mixed powders in a selective laser sintering system, select an appropriate three-dimensional model, spread the powders evenly on a substrate, and sinter layer by layer to finally obtain a polymer / GO / Ga scaffold with both anti-infection and osteogenic dual functions.
[0042] In this embodiment, in step 1, the mass volume ratio of gallium, HCL and ethylene glycol solution is 40 mg:20 μL:5 mL; the drying temperature under vacuum environment is 20° C., and the vacuum drying time is 12 hours.
[0043] In this embodiment, in step 2, the mass volume ratio of gallium, graphene oxide, HCL, and ethylene glycol solution is 40 mg:20 mg:20 μL:5 mL; the vacuum drying temperature is 40° C., and the vacuum drying time is 12 hours.
[0044] In this embodiment, in the step three, during the selective laser sintering process, the process parameters of the selective laser sintering are: laser power is 1-3W, scanning speed is 100-300mm / s, scanning spacing is 0.05-0.1mm, spot diameter is 0.3-1.0mm, and powder thickness is 0.05-0.15mm.
[0045] In this embodiment, the prepared polymer / GO / Ga scaffold has a porosity of 50-60% and a pore size of 200-500 μm.
[0046] In this embodiment, the prepared polymer / GO / Ga scaffold is applied in the field of biomedical materials.
[0047] Comparative Example 1
[0048] This comparative example provides a method for preparing a PLLA (polylactic acid) scaffold. First, the mass ratios of Ga and GO in Example 1 are measured to be 83wt% and 17wt%, respectively. In this comparative example, 100wt% PLLA is used as a raw material to prepare a PLLA scaffold. First, the PLLA powder is placed in a grinding mortar and ground for 10 minutes to allow the powders to be fully mixed to obtain a uniformly mixed PLLA powder.
[0049] 3D printing steps: Autodesk Inventor 3D modeling software was used to design a bracket model with a size of Φ6×2mm and a porosity of 50%. The bracket model was saved in .stl format and imported into the 3DPrinter control software of the selective laser sintering printing system. The printing parameters were set as follows: spot diameter 300μm, laser power 1.5W, scanning speed 200mm / s, and the evenly mixed PLLA powder was evenly spread on the substrate with a powder thickness of 0.05mm. After layer-by-layer sintering, the PLLA bracket was obtained.
[0050] Comparative Example 2
[0051] This comparative example provides a method for preparing a PLLA / GO scaffold. This comparative example uses 99.66wt% PLLA and 0.34wt% GO as raw materials to prepare the PLLA / GO scaffold; first, the PLLA powder and the GO powder are placed in a grinding mortar and ground for 10 minutes to fully mix the powders to obtain a uniformly mixed PLLA / GO powder, wherein the GO powder used in this comparative example is prepared in Example 1.
[0052] 3D printing steps: Autodesk Inventor 3D modeling software was used to design a scaffold model with a size of Φ6×2mm and a porosity of 50%. The scaffold model was saved in .stl format. The scaffold model was imported into the 3DPrinter control software of the selective laser sintering printing system, and the printing parameters were set: spot diameter 300μm, laser power 1.5W, scanning speed 200mm / s. The evenly mixed PLLA / GO powder was evenly spread on the substrate with a powder thickness of 0.05mm. After layer-by-layer sintering, the PLLA / GO scaffold was obtained.
[0053] Comparative Example 3
[0054] This comparative example provides a method for preparing a PLLA / Ga scaffold. This comparative example uses 98.34wt% PLLA and 1.66wt% Ga as raw materials to prepare the PLLA / Ga scaffold. First, PLLA powder and Ga powder are placed in a grinding mortar and ground for 10 minutes to fully mix the powders to obtain uniformly mixed PLLA / Ga powder.
[0055] 3D printing steps: Autodesk Inventor 3D modeling software was used to design a bracket model with a size of Φ6×2mm and a porosity of 50%. The bracket model was saved in .stl format and imported into the control software 3DPrinter of the selective laser sintering printing system. The printing parameters were set as follows: spot diameter 300μm, laser power 1.5W, scanning speed 200mm / s, and the evenly mixed PLLA / Ga powder was evenly spread on the substrate with a powder thickness of 0.05mm. After layer-by-layer sintering, the PLLA / Ga bracket was obtained.
[0056] The PLLA / GO / Ga scaffolds prepared in this example and PLLA, PLLA / GO, and PLLA / Ga scaffolds were co-cultured with Staphylococcus aureus (S. aureus) and Escherichia coli (E. coli) for 24 hours. Staphylococcus aureus (S. aureus, ATCC) and Escherichia coli (E. coli, ATCC) were selected for the antibacterial experiment. 1 μL of bacterial suspension (1×10 7 CFU) were inoculated into 999 μL LB medium containing different scaffolds and incubated in a 37°C incubator for 24 h. Subsequently, the bacterial solution was diluted 10 6times, and then the resulting mixture was added to the agar plate. After incubation at 37°C for another 24 h, digital photos of the plates containing Staphylococcus aureus and Escherichia coli were taken with a camera, and the number of colonies was counted using Image J software. The antibacterial effect of each scaffold group was evaluated using the formula: antibacterial efficiency = (1-t / T) × 100%, where t is the number of colonies in the experimental group and T is the number of colonies in the PLLA control group.
[0057] Antibacterial efficiency results Figure 3 As shown in Figure 2, it can be seen that the PLLA / GO / Ga scaffold exhibits a significant antibacterial effect because the PLLA / GO / Ga scaffold can continuously release Ga 3+ , the antibacterial effect is significant.
[0058] The PLLA / GO / Ga scaffold prepared in this embodiment, the PLLA scaffold prepared in comparative example 1, the PLLA / GO scaffold prepared in comparative example 2, and the PLLA / Ga scaffold prepared in comparative example 3 were respectively subjected to biocompatibility tests. Rat bone marrow mesenchymal stem cells (rBMSCs) were selected for the osteogenic experiment. The biocompatibility test was as follows: first, the sterilized PLLA / GO / Ga scaffold and PLLA, PLLA / GO, and PLLA / Ga scaffolds (Φ6mm×2mm) were respectively soaked in H-DMEM at a volume weight ratio of 40mL / g for 72h, and then the H-DMEM soaked with the materials was taken as the leaching solution for cell compatibility testing. 4 150 μL of cell suspension was inoculated into each well of a 96-well plate. After one day of culture, the culture medium was replaced with extracts of different scaffolds. After further culture for 1, 3, and 5 days, the cells were detected using a cell counting kit (CCK-8). Finally, the absorbance (OD value) at 450 nm was measured using an ELISA reader. The results are shown in Table 1. Figure 4 As shown, it can be seen that all four groups of stents showed good biocompatibility.
[0059] Alkaline phosphatase (ALP) staining experiment: The seeding density in each well of a 48-well plate was 2×10 4 500 μL of rBMSCs cell suspension was prepared. After culturing for 1 day, the culture medium was replaced with extracts of different scaffolds. The culture medium was changed every 2 days. After 7 days of osteogenic induction, the osteogenic differentiation ability of rBMSCs was detected by alkaline phosphatase (ALP) staining. The cells were washed with PBS and fixed with 4% paraformaldehyde at 37°C for 30 minutes. Subsequently, the ALP staining kit was used for the ALP staining experiment. The stained cells were observed under a fluorescence microscope, and the typical purple nodules were photographed. The staining results are shown in Figure 2. Figure 5-Figure 8As shown, it can be seen that the cells in the PLLA / GO / Ga scaffold group have more ALP expression, showing excellent osteogenic properties.
[0060] The number of devices and processing scales described here are used to simplify the description of the present invention. Applications, modifications and variations of the present invention will be obvious to those skilled in the art.
[0061] Although the embodiments of the present invention have been disclosed as above, they are not limited to the applications listed in the specification and the implementation modes, and they can be fully applied to various fields suitable for the present invention. For those familiar with the art, additional modifications can be easily implemented. Therefore, without departing from the general concept defined by the claims and the scope of equivalents, the present invention is not limited to the specific details and the illustrations shown and described herein.
Claims
1. A method for preparing a polymer / GO / Ga scaffold with dual functions of anti-infection and osteogenic differentiation, characterized in that: Firstly, GaNPs were adsorbed on the surface of GO nanosheets by electrostatic adsorption to prepare GO / Ga powder. Then, GO / Ga powder and polymer powder were ground and evenly mixed according to the proportion. Finally, selective laser sintering technology was used to prepare polymer / GO / Ga scaffold.
2. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 1, characterized in that: The high molecular polymer powder is at least one of left-handed polylactic acid PLLA powder, right-handed polylactic acid PDLA powder, racemic polylactic acid PDLLA powder, optically inactive polylactic acid Meso-PLA powder, polycaprolactone PCL powder, polyglycolic acid PGA powder, polylactic acid-glycolic acid copolymer PLGA powder and polydioxanone PPDO powder.
3. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 1, characterized in that: In the polymer / GO / Ga scaffold, the mass fraction of GO / Ga powder is 1-10wt%, the mass fraction of high molecular polymer powder is 90-99wt%, the particle size of GO / Ga powder is 0.1-2μm, and the particle size of high molecular polymer powder is 0.1-100μm.
4. The method for preparing the polymer / GO / Ga scaffold with dual functions of anti-infection and osteogenic differentiation according to any one of claims 1 to 3, characterized in that: The following steps are involved: Step 1: Gallium nanomaterials are prepared using nanoprobe ultrasonic technology. The specific method includes: heating metal gallium at 60°C for 10 minutes to obtain liquid metal gallium, and taking out 40 mg of liquid gallium from the liquid gallium and adding it to a glass bottle containing 20 μL 1 MHCL and 5 mL ethylene glycol. Ethylene glycol is used as a dispersion stabilizer for nanoparticles. Then, the solution is ultrasonicated for 2 hours (on for 15 seconds, off for 2 seconds) using a nanoprobe ultrasonic technology with a power of 150 W to obtain a GaNPs colloidal ethylene glycol solution (concentration of 8 mg / mL), which is centrifuged, washed with anhydrous ethanol, and dried under a vacuum environment to obtain Ga nanoparticles. Step 2: adsorbing GaNPs onto GO nanosheets by electrostatic adsorption to synthesize GO / Ga powder. The specific method includes: adding 20 mg of graphene oxide powder to the GaNPs colloidal ethylene glycol solution prepared above, and continuing to sonicate for 30 minutes (on for 15 seconds, off for 2 seconds) under a nanoprobe ultrasonic technology with a power of 150 W to obtain a GO / Ga colloidal ethylene glycol solution, and finally centrifuging, adding anhydrous ethanol for washing, and drying under a vacuum environment to obtain GO / Ga powder; Step 3: Weigh GO / Ga powder and high molecular polymer powder in a specific mass ratio as required, place them in a grinding mortar and grind them for 10 to 30 minutes to fully mix the powders. Then, place the evenly mixed powders in a selective laser sintering system, select an appropriate three-dimensional model, spread the powders evenly on a substrate, and sinter layer by layer to finally obtain a polymer / GO / Ga scaffold with both anti-infection and osteogenic dual functions.
5. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 4, characterized in that: In the step 1, the mass volume ratio of gallium, HCL and ethylene glycol solution is 40 mg:20 μL:5 mL; the drying temperature under vacuum environment is 20° C., and the vacuum drying time is 12 hours.
6. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 4, characterized in that: In the step 2, the mass volume ratio of gallium, graphene oxide, HCL, and ethylene glycol solution is 40 mg:20 mg:20 μL:5 mL; the vacuum drying temperature is 40° C., and the vacuum drying time is 12 hours.
7. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 4, characterized in that: In the step three, during the selective laser sintering process, the process parameters of the selective laser sintering are: laser power is 1-3W, scanning speed is 100-300mm / s, scanning spacing is 0.05-0.1mm, spot diameter is 0.3-1.0mm, and powder thickness is 0.05-0.15mm.
8. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 1, characterized in that: The prepared polymer / GO / Ga scaffold has a porosity of 50-60% and a pore size of 200-500 μm.
9. The method for preparing a polymer / GO / Ga scaffold having dual functions of anti-infection and osteogenic differentiation according to claim 1, characterized in that: The prepared polymer / GO / Ga scaffold is used in the field of biomedical materials.
Citation Information
Cited By
Liquid metal-based anti-inflammatory drug as well as preparation method and application thereof
CN119745919A
